$2.30
-0.23(-9.09%)
Mkt Cap $118M
$0.52
$4.20
52-Week Range
At a Glance
AI-generated8-K
enGene Holdings Inc. entered into a Sales Agreement with Leerink Partners LLC on March 9, 2026, to sell up to $100 million of common shares via at-the-market offerings and terminated its prior sales agreement with Jefferies LLC effective March 6, 2026, with no shares sold or penalties under the prior agreement.$118M
Market Cap
—
Revenue
-$27M
Net Income
Employees56
Fundamentals
How The Business Makes Money
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Industry Biotechnology
Activity
What Changed Recently
Company Profile
CIK0001980845
ISINCA29286M1133
CUSIP29286M113
Phone514 332 4888
Address7171 Rue Frederick Banting, Saint-Laurent, H4S 1Z9, CA
SEC EDGAR